jurgenfr
Shares of AVITA Medical (NASDAQ:RCEL) slid 14% post-market after the company issued updated 2024 and 2025 revenue guidance.
After market close, AVITA (NASDAQ:RCEL) said it now expects to report Q4 commercial revenue of around $18.4M, down from its previously issued range